Compare · HAE vs SYK
HAE vs SYK
Side-by-side comparison of Haemonetics Corporation (HAE) and Stryker Corporation (SYK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HAE and SYK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK is the larger of the two at $114.80B, about 37.6x HAE ($3.05B).
- HAE has been more active in the news (11 items in the past 4 weeks vs 8 for SYK).
- Both have 25 recent analyst ratings on file.
- Company
- Haemonetics Corporation
- Stryker Corporation
- Price
- $67.27-0.99%
- $299.36-1.92%
- Market cap
- $3.05B
- $114.80B
- 1M return
- +12.04%
- -
- 1Y return
- -2.22%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NYSE
- IPO
- 1991
- News (4w)
- 11
- 8
- Recent ratings
- 25
- 25
Haemonetics Corporation
Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx and El-Dorado Donor donation and blood unit management systems; Hemasphere software that provides support for blood drive planning; and Donor Doc and e-Donor software to enhance the donor recruitment and retention. In addition, the company offers hospital products comprising TEG diagnostic systems that enables clinicians to assess the coagulation status of a patient at the point-of-care or laboratory setting; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and BloodTrack, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Latest HAE
- SEC Form SD filed by Haemonetics Corporation
- Haemonetics upgraded by BofA Securities with a new price target
- SEC Form 10-K filed by Haemonetics Corporation
- EVP and General Counsel Basil Michelle L covered exercise/tax liability with 2,913 shares and was granted 28,424 shares, increasing direct ownership by 59% to 68,829 units (SEC Form 4) (tax withholding)
- EVP, Chief Operating Officer Chan Frank was granted 27,535 shares and covered exercise/tax liability with 546 shares, increasing direct ownership by 454% to 32,936 units (SEC Form 4) (tax withholding)
- EVP, Chief Financial Officer Darecca James covered exercise/tax liability with 2,505 shares and was granted 29,312 shares, increasing direct ownership by 97% to 54,444 units (SEC Form 4) (for withholding tax)
- VP, Chief Accounting Officer Maunsell Farris Maryanne covered exercise/tax liability with 197 shares and was granted 2,220 shares, increasing direct ownership by 45% to 6,501 units (SEC Form 4) to cover taxes
- EVP, Chief Commercial Officer Galvin Roy covered exercise/tax liability with 879 shares and was granted 27,535 shares, increasing direct ownership by 202% to 39,882 units (SEC Form 4) to satisfy withholding tax
- SVP, Human Resources Miller Laurie A. covered exercise/tax liability with 948 shares and was granted 13,323 shares, increasing direct ownership by 43% to 41,300 units (SEC Form 4) to cover withholding tax
- President & CEO Simon, Christopher covered exercise/tax liability with 9,681 shares and was granted 78,344 shares, increasing direct ownership by 18% to 444,704 units (SEC Form 4) (withholding obligation)
Latest SYK
- VP, Chief Legal Officer Fletcher Robert S sold $1,394,409 worth of shares (4,544 units at $306.87) as part of a pre-agreed trading plan, decreasing direct ownership by 30% to 10,582 units (SEC Form 4)
- Director Stryker Ronda E sold $96,792,669 worth of shares (310,000 units at $312.23) (SEC Form 4)
- Stryker Launches Pangea Plating System and Completes First Case in Europe
- SEC Form SD filed by Stryker Corporation
- SEC Form 8-K filed by Stryker Corporation
- BioStar Capital-Backed Amplitude Vascular Systems' $835M Acquisition by Stryker Reflects Strength of Michigan's Medtech Ecosystem
- VP, Chief HR Officer Fink M Kathryn exercised 21,582 shares at a strike of $167.98, covered exercise/tax liability with 16,362 shares and sold $2,473,756 worth of shares (8,720 units at $283.69) (SEC Form 4)
- SEC Form 10-Q filed by Stryker Corporation
- Director Suri Rajeev was granted 762 shares, increasing direct ownership by 12% to 7,190 units (SEC Form 4)
- Director Stryker Ronda E was granted 762 shares, increasing direct ownership by 136% to 1,322 units (SEC Form 4)